Medacta Group stock

MOVE · SIX · CHF

Compare Medacta Group
CHF 101.20Change from previous close: −1.75%Absolute change: −CHF 1.80

Close · November 20, 2026

Price history

−32.53% over the period

1 year: from CHF 150.00 (November 20, 2025) to CHF 101.20 (November 20, 2026), −32.53%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026CHF 101.20
October 30, 2026CHF 117.60
September 30, 2026CHF 114.20
August 31, 2026CHF 126.20
July 31, 2026CHF 132.00
June 30, 2026CHF 136.00
May 29, 2026CHF 143.20
April 30, 2026CHF 141.60
March 31, 2026CHF 149.60
February 27, 2026CHF 159.40
January 30, 2026CHF 165.20
December 30, 2025CHF 156.40
November 28, 2025CHF 154.80
November 20, 2025CHF 150.00

At a glance

  • The company

    Develops, manufactures and distributes orthopedic and neurosurgical medical devices globally

  • Latest results

    Quarter to June 30, 2026 · EPS €2.10

TickerLandia's take on Medacta Group

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowCHF 100.60
52-wk highCHF 177.20

−42.89% from the 52-week high

Analysts · 6 analysts

Average targetCHF 149.05+47.28% vs. price

Buy 4 · Hold 2 · Sell 0 · Buy

TickerLandia Fingerprint: Medacta Group

Compared with similar companies: very weak momentum and very high risk.

Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Medacta Group is in line with similar companies

Medacta Group's P/E (trailing 12 months): 27.7, in line with the median of a group of 10 similar companies (28.9).

Compared with 10 similar companies

Medacta Group's metrics compared with similar companies
MetricMedacta GroupPosition in the groupBand
P/E (trailing 12 months)27.7Middle
Forward P/E19.9Middle
Operating margin15.2%Middle
ROE17.0%Middle
Debt/equity0.66Middle

Grey band: the middle half of the group; tick: the median; dot: Medacta Group. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€368.17M

Latest quarter · Q2 2026

Net income

€41.86M

Latest quarter · Q2 2026

Quarterly net margin

11.4%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
CHF 2.02B
P/E
27.7
EPS
CHF 3.65
Volume
24.75K
Daily trading
€4.83M
Dividend yield
1.09%
Last ex-dividend on May 7, 2026

How Medacta Group is changing

All results
  • Revenue grew 17.7% a year on average over the last 5 years

  • Less cash than profit: free cash flow equal to 25% of net income

  • Revenue has grown for 5 fiscal years in a row

Returns

Medacta Group returns with dividends

CHF 1,000 invested in Medacta Group 5 years ago, on November 22, 2021, would be worth CHF 748 today with dividends reinvested: −25.21% in total, −5.65% per year. On price alone it would be CHF 728 (−27.19%).

PeriodMedacta GroupSMICHF 1,000 becomes
1 month−12.91%+0.65%CHF 871
6 months−30.49%+8.75%CHF 695
Year to date−35.29%+9.83%CHF 647
1 year−32.00%+16.18%CHF 680
3 years−12.28%+35.68%CHF 877
5 years−25.21%+16.48%CHF 748

Over the last 6 months it has done better than 3% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment

The chart in detail

Medacta Group: technical analysis

Medacta Group is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 42.5% below its all-time closing high (CHF 176.00, January 23, 2026).

Trend
Downward
RSI (14 sessions)
29
Below 30: a strong fall in a short time
vs 200-session average
−24.69%

Active signals

  • New 52-week low.

    since November 19, 2026

  • Close below the low of the previous 55 sessions.

    since November 19, 2026

  • RSI below 30: the stock has fallen a lot in a short time.

Support and resistance

Price areas where Medacta Group has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. ResistanceCHF 139.10+37.45%2 touches, last on July 30, 2026
  2. ResistanceCHF 132.93+31.36%3 touches, last on September 4, 2026
  3. ResistanceCHF 128.67+27.14%3 touches, last on July 21, 2026
  4. Last priceCHF 101.20
  5. No support below: the price is near the lows of the year

Volatility and risk

Over the last year it has moved roughly in line with the SMI.

Beta (1 year) vs SMI
1.03
Volatility (60 sessions, annualised)
39.1%
Largest fall in the last year
−42.50%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Medacta Group: seasonality

Average monthly price change over 8 years

+3.0%Jan+1.2%Feb−6.9%Mar+6.5%Apr+2.8%May−2.3%Jun+4.3%Jul−1.4%Aug−2.0%Sep−1.3%Oct+3.5%Nov+0.6%Dec

Over the last 8 years, the strongest month for Medacta Group has been April: +6.51% on average, positive in 5 years out of 7. The weakest has been March: −6.91% on average, positive in 0 years out of 7. November, the current month, has been positive in 5 years out of 7 (+3.50% on average).

Show chart data
MonthAverageMedianPositive years
January+3.01%+5.63%5 of 7
February+1.17%−1.18%3 of 7
March−6.91%−3.66%0 of 7
April+6.51%+5.38%5 of 7
May+2.75%+1.24%5 of 8
June−2.33%−1.34%2 of 8
July+4.34%+3.62%6 of 8
August−1.36%−2.17%3 of 8
September−2.03%−1.31%4 of 8
October−1.34%+0.48%4 of 8
November+3.50%+4.09%5 of 7
December+0.58%+1.51%5 of 7

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Medacta Group and its competitors

Medacta Group SA serves customers in Latin America, North America, the Asia-Pacific region, and the Middle East and Africa with orthopedic and neurosurgical medical devices. The company develops, manufactures and distributes these products, and it complements them with personalized 3D planning tools for hip, knee and shoulder joint replacement, sports medicine and spine surgery. Its offering thus combines physical devices with digital planning tools used before surgery.

Headquarters
Castel San Pietro, Switzerland
Employees
2,273
Founded
1958
Chief executive
Francesco Siccardi
Medacta Group and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Medacta GroupMOVE$2.41B15.2%27.7−30.49%
ElektaEKTA.B$2.27B9.2%—+1.17%
GN Store NordGN$2.46B10.9%90.2+22.10%
ChemoMetecCHEMM$1.75B49.1%59.9+99.42%
AmbuAMBU.B$3.4B13.2%36.7+32.33%
El.En.ELN$1.44B14.7%20.7+10.78%

Same industry or related industries, similar size. Compare Medacta Group with its competitors · Full profile